CARDAX, INC.
CARDAX, INC. (CDXI): 2 pipeline candidates · ~3 mo cash runway. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
3.3 months
D/E -1.12 · 0% dilution
Lead: Preclinical
2 candidates
N/A
N/A
A transparent, data-derived signal for CARDAX, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$80
Cash
$59K
Quarterly Burn
$337K
Runway
3.3 mo
Revenue
$105K
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Frequently asked questions
How many drug candidates are in CARDAX, INC.'s pipeline?
CARDAX, INC. (CDXI) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is CARDAX, INC.'s lead drug candidate?
CARDAX, INC.'s most advanced tracked candidate is cdx-101 (Preclinical) for cardiovascular inflammation and dyslipidemia.
What is CARDAX, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, CARDAX, INC. has approximately 3.3 months of cash runway.
What is CARDAX, INC.'s market capitalization?
CARDAX, INC.'s market capitalization is approximately $80.
Who is the CEO of CARDAX, INC.?
Mr. David G. Watumull is the chief executive officer of CARDAX, INC. (CDXI).
Get the full picture on CARDAX, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.